Výsledky vyhledávání

Akademický článek

Acellular and 'low' pertussis vaccines: adverse events and the role of mutations Vacinas pertussis acelular e pertussis 'low': eventos adversos e o papel das mutações

Autor: Hisako G. Higashi, Expedito Luna, Alexander R. Precioso, Marluce Vilela, Flávia S. Kubrusly, Waldely O. Dias, Isaias Raw

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo, Vol 51, Iss 3, Pp 131-134 (2009)

Objective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like

Externí odkaz: https://doaj.org/article/a55c32db4d734c189f57dae9a790dd21

Zobrazit plný text záznamu

Akademický článek

Auto-suficiência e inovação na produção de vacinas e saúde pública Self-sufficiency and innovation in vaccine production and public health

Autor: Isaias Raw, Hisako G. Higashi

Publikováno v: Estudos Avançados, Vol 22, Iss 64, Pp 155-170 (2008)

Externí odkaz: https://doaj.org/article/14c2a2c8bd38473a97125767495a8f08

Zobrazit plný text záznamu

Akademický článek

Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil.

Autor: Paulo Lee Ho, Eliane Namie Miyaji, Maria Leonor Sarno Oliveira, Waldely de Oliveira Dias, Flavia Saldanha Kubrusly, Martha Massako Tanizaki, Elizabeth Angélica Leme Martins, Isaias Raw

Publikováno v: PLoS Neglected Tropical Diseases, Vol 5, Iss 11, p e1300 (2011)

Externí odkaz: https://doaj.org/article/3e04f99027e8498d83ac947734a106d6

Zobrazit plný text záznamu

Akademický článek

Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients.

Publikováno v: PLoS ONE, Vol 6, Iss 11, p e27214 (2011)

BackgroundImmunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety and immunogenicity of influenza vaccination among them.MethodsThis multicenter cohort study evaluated th

Externí odkaz: https://doaj.org/article/a521253f5a8a48878f105bf9684f2625

Zobrazit plný text záznamu

Akademický článek

Safety and immunogenicity of hepatitis B vaccine ButaNG in adults

Autor: Luzia M. IOSHIMOTO, Maria Lúcia RISSATO, Valentina S.J. BONILHA, Cosue MIYAKI, Isaias RAW, Nikolai GRANOVSKI

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo, Vol 41, Iss 3, Pp 191-193 (1999)

Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 mg doses and 0, 1, 3 months vaccinat

Externí odkaz: https://doaj.org/article/10287d1c22004cd68e20cce398c315bc

Zobrazit plný text záznamu

Akademický článek

A UTILIZAÇÃO DO ANTI-CD3 BUTANTAN NO TRANSPLANTE RENAL

Autor: Francine Lemos, Flavio Marques, Maria Cristina Ribeiro Castro, Luiz Estevam Ianhez, Ana Maria Moro, Maria Teresa Alves Rodrigues, Angélica Garbuio, Isaias Raw, Sandra Maria Monteiro, Verônica Coelho, Jorge Kalil, Jose Osmar Medina Pestana, Valter Duro Garcia, Jorge Neumann

Publikováno v: Brazilian Journal of Transplantation, Vol 9, Iss 3 (2006)

Objetivos: O anticorpo monoclonal anti-CD3 tem sido empregado na prevenção e tratamento de episódios de rejeição aguda em transplante de órgãos. Neste estudo retrospectivo, relatamos a experiência de três instituições brasileiras que utili

Externí odkaz: https://doaj.org/article/8a7a4df7db9b4e58b1965cb7c66e607c

Zobrazit plný text záznamu

Akademický článek

PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

Autor: Angela Aparecida COSTA, Marta INENAMI, Edmundo JUAREZ, Pedro Dorlhiac LLACEN, Isaias RAW

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo, Vol 39, Iss 1, p 39 (1997)

Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical

Externí odkaz: https://doaj.org/article/8a0e29a3fea846caaedc141c761b9fec

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání